Nextcure Inc (NXTC) Stock Price, Quote & News

Company Profile

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease;...

Industry: Biotechnology

Sector: Healthcare

Phone: 240 399 4900

Website: www.nextcure.com

Address:

9000 Virginia Manor Road, Suite 200, Beltsville, United States

neilyoungsband Mar. 6 at 10:49 AM

$NXTC burn!!!!!

0 · Reply

d_risk Mar. 5 at 9:34 PM

$NXTC - NextCure, Inc. - 10K - Updated Risk Factors NXTC’s risks now highlight severe going-concern uncertainty, a larger $436M accumulated deficit with only $41.8M cash, immediate-term funding needs, and potential liquidation, alongside new SIM0505-focused clinical and commercialization risks and heightened exposure to fast-changing US drug pricing and FDA policies. #Biotechnology #FinancialRisk #ClinicalTrials #DrugPricing #RegulatoryRisk 🟢 Added 🟠 Removed https://d-risk.ai/NXTC/10-K/2026-03-05

0 · Reply

StockNews_Live Mar. 5 at 9:07 PM

$NXTC NextCure, Inc. provided a business update and reported full year 2025 financial results. The company anticipates 2026 to be transformational, with clinical dose escalation data from the Phase 1 trial …

0 · Reply

BillionerOfKing Mar. 4 at 5:38 PM

$NXTC Current Stock Price: $12.45

0 · Reply

neilyoungsband Mar. 2 at 2:52 PM

$NXTC burn!!!!!

0 · Reply

OfficialStocktwitsUser Feb. 24 at 11:56 PM

$NXTC RSI: 62.97, MACD: 0.3402 Vol: 1.16, MA20: 12.13, MA50: 12.42 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

emeraldstocktrader Feb. 22 at 11:42 PM

$NXTC has a promising candidate in this space CDH6... and MSD acquired assets including a CDH6 for 22B ... bullish!

0 · Reply

emeraldstocktrader Feb. 19 at 7:11 PM

$NXTC buy alert! This drug is worth 50x based on comps!!

1 · Reply

neilyoungsband Feb. 3 at 2:37 PM

$NXTC buying at .10 cents burn this pos to the ground.

0 · Reply

emeraldstocktrader Feb. 2 at 4:15 PM

$NXTC buying here 🚨

0 · Reply

NextCure Provides Business Update and Reports Full Year 2025 Financial Results

Jan 23, 2026, 7:00 AM EST - 7 weeks ago

NextCure Provides Business Update

Nov 20, 2025, 8:00 AM EST - 4 months ago

NextCure to Present at the Piper Sandler 37th Annual Healthcare Conference

Nov 17, 2025, 8:00 AM EST - 4 months ago

NextCure Announces Closing of $21.5 Million PIPE Financing in Advance of First Half 2026 Phase 1 POC Data Readouts

Nov 12, 2025, 8:00 AM EST - 4 months ago

NextCure Announces $21.5 Million Private Placement of Common Stock Priced at the Market Under Nasdaq Rules

Nov 5, 2025, 4:05 PM EST - 4 months ago

NextCure Provides Business Update and Reports Third Quarter 2025 Financial Results

Oct 16, 2025, 8:05 AM EDT - 5 months ago

NextCure and Simcere Zaiming Announce Expansion of Ongoing Phase 1 Trial of SIM0505 (CDH6 ADC) into the United States

Sep 4, 2025, 7:00 AM EDT - 6 months ago

NextCure to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 7, 2025, 4:05 PM EDT - 7 months ago

NextCure Provides Business Update and Reports Second Quarter 2025 Financial Results

Jul 24, 2025, 4:05 PM EDT - 8 months ago

Preclinical Data Demonstrate Anti-Siglec-15 Treatment Improves Bone Microarchitecture and Reduces Fracture Incidence in Mice with Moderate-to-Severe Osteogenesis Imperfecta

Jun 16, 2025, 10:03 AM EDT - 9 months ago

NextCure signs up to $745 million deal with China's Simcere to develop cancer drug

Jun 16, 2025, 7:05 AM EDT - 9 months ago

NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6

May 29, 2025, 4:05 PM EDT - 10 months ago

NextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025

May 1, 2025, 4:05 PM EDT - 11 months ago

NextCure Provides Business Update and Reports First Quarter 2025 Financial Results

Apr 4, 2025, 7:00 AM EDT - 1 year ago

NextCure to Present at 24th Annual Needham Virtual Healthcare Conference

Mar 6, 2025, 4:05 PM EST - 1 year ago

NextCure Provides Business Update and Reports Full Year 2024 Financial Results

Jan 10, 2025, 8:05 AM EST - 1 year ago

NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers

Dec 10, 2024, 8:05 AM EST - 1 year ago

NextCure Announces Acceptance of IND Application for LNCB74

Nov 26, 2024, 7:00 AM EST - 1 year ago

NextCure to Participate in the 36th Annual Piper Sandler Healthcare Conference

Nov 19, 2024, 8:05 AM EST - 1 year ago

Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis Imperfecta

Nov 7, 2024, 4:05 PM EST - 1 year ago

NextCure Provides Business Update and Reports Third Quarter 2024 Financial Results

Nov 5, 2024, 4:05 PM EST - 1 year ago

NextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual Meeting

Oct 4, 2024, 9:05 AM EDT - 1 year ago

NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting

Sep 16, 2024, 8:05 AM EDT - 1 year ago

NextCure Presented Results of the Phase 1b Study of NC410 in Combination with Pembrolizumab at ESMO 2024

Jun 20, 2024, 4:10 PM EDT - 1 year ago

NextCure to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

May 30, 2024, 4:05 PM EDT - 1 year ago

NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024

May 2, 2024, 4:05 PM EDT - 2 years ago

NextCure Provides Business Update and Reports First Quarter 2024 Financial Results

Apr 24, 2024, 4:05 PM EDT - 2 years ago

NextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024

Apr 8, 2024, 7:00 AM EDT - 2 years ago

NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024

Apr 4, 2024, 7:05 AM EDT - 2 years ago

NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board

Apr 2, 2024, 7:00 AM EDT - 2 years ago

NextCure to Present at 23rd Annual Needham Virtual Healthcare Conference

Mar 21, 2024, 8:55 AM EDT - 2 years ago

NextCure Provides Business Update and Reports Full Year 2023 Financial Results

Mar 5, 2024, 8:05 AM EST - 2 years ago

NextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science Advances

Jan 18, 2024, 4:05 PM EST - 2 years ago

NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders

Dec 21, 2023, 7:05 AM EST - 2 years ago

NextCure Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injury

Dec 14, 2023, 6:45 AM EST - 2 years ago

NextCure Provides Year-End Clinical Pipeline Updates

Nov 20, 2023, 7:00 AM EST - 2 years ago

NextCure to Present at the 35th Annual Piper Sandler Healthcare Conference

Nov 15, 2023, 4:05 PM EST - 2 years ago

NextCure Publishes Non-Clinical Data Defining the Mechanism of Action for NC525, a Novel LAIR-1 Antibody for AML

Nov 2, 2023, 4:05 PM EDT - 2 years ago

NextCure Provides Business Update and Reports Third Quarter 2023 Financial Results

Oct 17, 2023, 8:05 AM EDT - 2 years ago

Preclinical Data Demonstrate Anti-Siglec-15 Treatment Reduced Bone Loss and Enhanced Bone Quality in Mice with Moderate-to-Severe Osteogenesis Imperfecta (OI)

Sep 26, 2023, 4:05 PM EDT - 2 years ago

NextCure Presents Preclinical Data on NC181, a Novel Therapeutic Candidate Targeting ApoE4, for the Treatment of Alzheimer's Disease

$A Phase 2 Study of Anti-Siglec-15 Antibody, NC318, in Combination with Pembrolizumab (NCT04699123) Demonstrates Clinical Activity in Patients with Advanced PD-1 Axis Inhibitor Refractory NSCLC$

Sep 12, 2023, 8:05 AM EDT - 2 years ago

A Phase 2 Study of Anti-Siglec-15 Antibody, NC318, in Combination with Pembrolizumab (NCT04699123) Demonstrates Clinical Activity in Patients with Advanced PD-1 Axis Inhibitor Refractory NSCLC

Sep 7, 2023, 4:05 PM EDT - 2 years ago

NextCure and Nordic Bioscience Publish Review Article on the Regulation of Tumor Immunity by Tumor Collagen

Sep 5, 2023, 4:05 PM EDT - 2 years ago

Preclinical Data Demonstrate Potential Application of Anti-Siglec-15 Treatment in Bone Disease

Aug 31, 2023, 7:00 AM EDT - 2 years ago

NextCure to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 3, 2023, 4:05 PM EDT - 2 years ago

NextCure Provides Business Update and Reports Second Quarter 2023 Financial Results

Jun 21, 2023, 4:05 PM EDT - 2 years ago

NextCure Presents Non-Clinical Data Defining the Mechanism of NC525 at the 2023 Federation of Clinical Immunology Societies (FOCIS) Annual Meeting

May 9, 2023, 7:00 AM EDT - 3 years ago

NextCure to Present at the JMP Securities Life Sciences Conference

May 4, 2023, 4:05 PM EDT - 3 years ago

NextCure Provides Business Update and Reports First Quarter 2023 Financial Results

Apr 11, 2023, 7:00 AM EDT - 3 years ago

NextCure to Present at 22nd Annual Needham Virtual Healthcare Conference

neilyoungsband Mar. 6 at 10:49 AM

$NXTC burn!!!!!

0 · Reply

d_risk Mar. 5 at 9:34 PM

0 · Reply

StockNews_Live Mar. 5 at 9:07 PM

0 · Reply

BillionerOfKing Mar. 4 at 5:38 PM

$NXTC Current Stock Price: $12.45

0 · Reply

neilyoungsband Mar. 2 at 2:52 PM

$NXTC burn!!!!!

0 · Reply

OfficialStocktwitsUser Feb. 24 at 11:56 PM

0 · Reply

emeraldstocktrader Feb. 22 at 11:42 PM

$NXTC has a promising candidate in this space CDH6... and MSD acquired assets including a CDH6 for 22B ... bullish!

0 · Reply

emeraldstocktrader Feb. 19 at 7:11 PM

$NXTC buy alert! This drug is worth 50x based on comps!!

1 · Reply

neilyoungsband Feb. 3 at 2:37 PM

$NXTC buying at .10 cents burn this pos to the ground.

0 · Reply

emeraldstocktrader Feb. 2 at 4:15 PM

$NXTC buying here 🚨

0 · Reply

PickAlpha Jan. 24 at 2:49 PM

3/4: NextCure reports ~$41.8M year-end cash, guides funding runway into 1H 2027 | View: Extended runway into 1H 2027 eases near-term dilution risk… $NXTC $XBI

0 · Reply

BillionerOfKing Jan. 20 at 11:51 PM

$NXTC Current Stock Price: $13.34

0 · Reply

emeraldstocktrader Jan. 14 at 6:11 PM

$NXTC 🚨 love it

1 · Reply

emeraldstocktrader Dec. 31 at 6:11 PM

$NXTC buying here 🚨

2 · Reply

kshonstocks Dec. 30 at 4:50 PM

$NXTC 97 name on scans https://research.investors.com/stock-quotes/nasdaq-nextcure-nxtc.htm

0 · Reply

SuperGreenToday Dec. 30 at 3:59 AM

$NXTC

0 · Reply

DunnDunn86 Dec. 29 at 7:49 PM

$NXTC What happened suddenly, jumped 5% ... gl ✨

1 · Reply

GlacierGuard Dec. 26 at 5:08 PM

$NXTC Price action signals that reliability now matters more than headline momentum. Margin trajectory needs to confirm that scale creates leverage, not dilution. Overextension would degrade optionality during downturns. Sentiment should follow consistency rather than noise.

0 · Reply

HieronymusBosch Dec. 12 at 3:27 PM

$NXTC loving this

0 · Reply

Market Cap	45.15M
Revenue (ttm)	0.00
Net Income (ttm)	-55.84M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	22,900
Avg Vol	36,192
Day's Range	N/A - N/A
Shares Out	3.56M
Stochastic %K	38%
Beta	1.50
Analysts	Strong Sell
Price Target	$17.67